Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. The post Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases appeared first on MedCity News.
Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies.
The post Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases appeared first on MedCity News.
